EP 1347761 A2 20031001 - PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES
Title (en)
PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES
Title (de)
PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND THIENOPYRIMIDINE UND ANTITHROMBOTICA, CALCIUM-ANTAGONISTEN, PROSTAGLANDINE ODER PROSTAGLANDINDERIVATE
Title (fr)
FORMULATION PHARMACEUTIQUE CONTENANT DES THIENOPYRIMIDINES ET DES ANTITHROMBOTIQUES, DES INHIBITEURS CALCIQUES, DES PROSTAGLANDINES OU DES DERIVES DE PROSTAGLANDINE (1)
Publication
Application
Priority
- DE 10063223 A 20001219
- DE 10063885 A 20001221
- DE 10064992 A 20001223
- EP 0113915 W 20011128
Abstract (en)
[origin: WO0249650A2] The invention relates to a pharmaceutical preparation containing at least one compound of formula (I) wherein R<1>, R<2>, R<3>, R<4>, n and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, atheriosclerosis, conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems.
IPC 1-7
IPC 8 full level
A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/14 (2006.01); A61P 7/02 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 9/14 (2006.01); A61P 11/00 (2006.01); A61P 11/02 (2006.01); A61P 11/06 (2006.01); A61P 13/12 (2006.01); A61P 15/08 (2006.01); A61P 15/10 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP KR US)
A61K 31/519 (2013.01 - EP KR US); A61K 45/06 (2013.01 - EP US); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 3/14 (2018.01 - EP); A61P 7/02 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/04 (2018.01 - EP); A61P 9/08 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 9/14 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/02 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 15/08 (2018.01 - EP); A61P 15/10 (2018.01 - EP); A61P 27/06 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 39/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP)
C-Set (source: EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0249650 A2 20020627; WO 0249650 A3 20021031; AR 032009 A1 20031022; AU 2795702 A 20020701; BR 0116255 A 20031230; CA 2431074 A1 20020627; CN 1481242 A 20040310; CZ 20031754 A3 20030917; EP 1347761 A2 20031001; HU P0303289 A2 20040128; JP 2004516269 A 20040603; KR 20030059351 A 20030707; MX PA03005405 A 20030925; NO 20032772 D0 20030618; NO 20032772 L 20030618; PL 361805 A1 20041004; SK 8082003 A3 20031007; US 2004072846 A1 20040415
DOCDB simple family (application)
EP 0113915 W 20011128; AR P010105887 A 20011219; AU 2795702 A 20011128; BR 0116255 A 20011128; CA 2431074 A 20011128; CN 01820820 A 20011128; CZ 20031754 A 20011128; EP 01989533 A 20011128; HU P0303289 A 20011128; JP 2002550990 A 20011128; KR 20037008155 A 20030618; MX PA03005405 A 20011128; NO 20032772 A 20030618; PL 36180501 A 20011128; SK 8082003 A 20011128; US 45111803 A 20030619